Development of Therapeutic Antibodies and Modulating the Characteristics of Therapeutic Antibodies to Maximize the Therapeutic Efficacy

Overview

Journal Biotechnol Bioprocess Eng

Specialty Biomedical Engineering

Date 2021 Jul 5

PMID 34220207

Citations 8

Authors

Seung Hyun Kang

Chang-Han Lee

Affiliations

Soon will be listed here.

Abstract

Monoclonal antibodies (mAb) have been used as therapeutic agents for various diseases, and immunoglobulin G (IgG) is mainly used among antibody isotypes due to its structural and functional properties. So far, regardless of the purpose of the therapeutic antibody, wildtype IgG has been mainly used, but recently, the engineered antibodies with various strategies according to the role of the therapeutic antibody have been used to maximize the therapeutic efficacy. In this review paper, first, the overall structural features and functional characteristics of antibody IgG, second, the old and new techniques for antibody discovery, and finally, several antibody engineering strategies for maximizing therapeutic efficacy according to the role of a therapeutic antibody will be introduced.

Citing Articles

Formation of mono- and dual-labelled antibody fragment conjugates reversible site-selective disulfide modification and proximity induced lysine reactivity.

Thanasi I, Bouloc N, McMahon C, Wang N, Szijj P, Butcher T Chem Sci. 2025; 16(6):2763-2776.

PMID: 39811008 PMC: 11726237. DOI: 10.1039/d4sc06500j.

Construction and validation of a synthetic phage-displayed nanobody library.

Kim M, Bai X, Im H, Yang J, Kim Y, Kim M Korean J Physiol Pharmacol. 2024; 28(5):457-467.

PMID: 39198226 PMC: 11361996. DOI: 10.4196/kjpp.2024.28.5.457.

Chemo- and regio-selective differential modification of native cysteines on an antibody the use of dehydroalanine forming reagents.

Yap S, Butcher T, Spears R, McMahon C, Thanasi I, Baker J Chem Sci. 2024; 15(22):8557-8568.

PMID: 38846383 PMC: 11151841. DOI: 10.1039/d4sc00392f.

Development of a new affinity maturation protocol for the construction of an internalizing anti-nucleolin antibody library.

Ribeiro R, Moreira J, Goncalves J Sci Rep. 2024; 14(1):10608.

PMID: 38719911 PMC: 11079059. DOI: 10.1038/s41598-024-61230-z.

Enhanced delivery of a low dose of aducanumab via FUS in 5×FAD mice, an AD model.

Kong C, Yang E, Shin J, Park J, Kim S, Park S Transl Neurodegener. 2022; 11(1):57.

PMID: 36575534 PMC: 9793531. DOI: 10.1186/s40035-022-00333-x.

References

Weiner L, Surana R, Wang S . Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010; 10(5):317-27. PMC: 3508064. DOI: 10.1038/nri2744. View

Georgiou G, Ippolito G, Beausang J, Busse C, Wardemann H, Quake S . The promise and challenge of high-throughput sequencing of the antibody repertoire. Nat Biotechnol. 2014; 32(2):158-68. PMC: 4113560. DOI: 10.1038/nbt.2782. View

Bruhns P, Jonsson F . Mouse and human FcR effector functions. Immunol Rev. 2015; 268(1):25-51. DOI: 10.1111/imr.12350. View

Lefranc M, Lefranc G . Human Gm, Km, and Am allotypes and their molecular characterization: a remarkable demonstration of polymorphism. Methods Mol Biol. 2012; 882:635-80. DOI: 10.1007/978-1-61779-842-9_34. View

Coronella J, Telleman P, Truong T, Ylera F, Junghans R . Amplification of IgG VH and VL (Fab) from single human plasma cells and B cells. Nucleic Acids Res. 2000; 28(20):E85. PMC: 110801. DOI: 10.1093/nar/28.20.e85. View

Goulet D, Atkins W . Considerations for the Design of Antibody-Based Therapeutics. J Pharm Sci. 2019; 109(1):74-103. PMC: 6891151. DOI: 10.1016/j.xphs.2019.05.031. View

de Taeye S, Bentlage A, Mebius M, Meesters J, Lissenberg-Thunnissen S, Falck D . FcγR Binding and ADCC Activity of Human IgG Allotypes. Front Immunol. 2020; 11:740. PMC: 7218058. DOI: 10.3389/fimmu.2020.00740. View

Kohler G, Milstein C . Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975; 256(5517):495-7. DOI: 10.1038/256495a0. View

Liu J, Wang G, Liu L, Wu R, Wu Y, Fang C . Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor. Sci Rep. 2019; 9(1):17830. PMC: 6882818. DOI: 10.1038/s41598-019-54231-w. View

10.

Wang W, Singh S, Zeng D, King K, Nema S . Antibody structure, instability, and formulation. J Pharm Sci. 2006; 96(1):1-26. DOI: 10.1002/jps.20727. View

11.

Rothe C, Urlinger S, Lohning C, Prassler J, Stark Y, Jager U . The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies. J Mol Biol. 2008; 376(4):1182-200. DOI: 10.1016/j.jmb.2007.12.018. View

12.

Love J, Ronan J, Grotenbreg G, van der Veen A, Ploegh H . A microengraving method for rapid selection of single cells producing antigen-specific antibodies. Nat Biotechnol. 2006; 24(6):703-7. DOI: 10.1038/nbt1210. View

13.

Stavenhagen J, Gorlatov S, Tuaillon N, Rankin C, Li H, Burke S . Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res. 2007; 67(18):8882-90. DOI: 10.1158/0008-5472.CAN-07-0696. View

14.

Braig F, Brandt A, Goebeler M, Tony H, Kurze A, Nollau P . Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood. 2016; 129(1):100-104. DOI: 10.1182/blood-2016-05-718395. View

15.

Tabasinezhad M, Talebkhan Y, Wenzel W, Rahimi H, Omidinia E, Mahboudi F . Trends in therapeutic antibody affinity maturation: From in-vitro towards next-generation sequencing approaches. Immunol Lett. 2019; 212:106-113. DOI: 10.1016/j.imlet.2019.06.009. View

16.

Eyer K, Doineau R, Castrillon C, Briseno-Roa L, Menrath V, Mottet G . Single-cell deep phenotyping of IgG-secreting cells for high-resolution immune monitoring. Nat Biotechnol. 2017; 35(10):977-982. DOI: 10.1038/nbt.3964. View

17.

Matlung H, Babes L, Zhao X, Van Houdt M, Treffers L, van Rees D . Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis. Cell Rep. 2018; 23(13):3946-3959.e6. DOI: 10.1016/j.celrep.2018.05.082. View

18.

Schmid A, Neri D . Advances in antibody engineering for rheumatic diseases. Nat Rev Rheumatol. 2019; 15(4):197-207. DOI: 10.1038/s41584-019-0188-8. View

19.

Prassler J, Thiel S, Pracht C, Polzer A, Peters S, Bauer M . HuCAL PLATINUM, a synthetic Fab library optimized for sequence diversity and superior performance in mammalian expression systems. J Mol Biol. 2011; 413(1):261-78. DOI: 10.1016/j.jmb.2011.08.012. View

20.

Kwakkenbos M, Diehl S, Yasuda E, Bakker A, van Geelen C, Lukens M . Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat Med. 2009; 16(1):123-8. PMC: 2861345. DOI: 10.1038/nm.2071. View